The win ratio: A new approach to the analysis of composite endpoints in clinical trials based on clinical priorities

European Heart Journal

Volumn 33, Issue 2, 2012, Pages 176-182

  Pocock, Stuart J ^a   Ariti, Cono A ^a   Collier, Timothy J ^a   Wang, Duolao ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Clinical trials; Composite endpoints; Heart failure; Statistical analysis; Trial reporting

Indexed keywords

CANDESARTAN; EPLERENONE; PLACEBO;

AORTA STENOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); COMPOSITE ENDPOINT; DETERIORATION; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; METHODOLOGY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL CONCEPTS; TRANSCATHETER AORTIC VALVE IMPLANTATION; WIN RATIO;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; AORTIC VALVE STENOSIS; BENZIMIDAZOLES; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HEART CATHETERIZATION; HEART FAILURE; HOSPITALIZATION; HUMANS; MATCHED-PAIR ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SPIRONOLACTONE; TETRAZOLES;

EID: 84862942215     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr352     Document Type: Article

References (12)

1. Montori VN, Permanyer-Miralda G, Ferreira-Gonzalez I, Busse JW, Pacheco-Huergo V, Bryant D, Alonso J, Akl EA, Domingo-Salvany A, Mills E, Wu P, Schunemann HJ, Jaeschke R, Guyatt GH. Validity of composite end points in clinical trials. BMJ 2005;330:594-596. (Pubitemid 40380357)
2. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty?. JAMA 2003; 289:2554-2559. (Pubitemid 37430157)
3. Ferreira-González I, Permanyer-Miralda G, Busse JW, Bryant DM, Montori VM, Alonso-Coelho P, Walter SD, Guyatt GH. Methodologic discussions for using and interpreting endpoints are limited, but still identify major concerns. J Clin Epidemiol 2007;60:651-657. (Pubitemid 46901008)
4. Ferreira-González I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, Alonson J, Worster A, Upadhye S, Jaeschke R, Schunemann HJ, Permanyer-Miralda G, Pacheco-Huergo V, Domingo-Salvany A, Wu P, Mills EJ, Guyatt GH. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ 2007;334:786-792.
5. Neaton JD, Gray G, Zuckerman BD, Konstam MA. Key issues in end point selection for heart failure trials: composite end points. J Card Fail 2005;11:567-575. (Pubitemid 41463726)
6. Lubsen J, Kirwan BA. Combined endpoints: can we use them?. Stat Med 2002;21: 2959-2970.
7. Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med 1999;18:1341-1354. (Pubitemid 29261493)
8. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparison in clinical trial reporting: current practice and problems. Stat Med 2002;21:2917-2930.
9. Ford I, Norrie J. The role of covariates in estimating treatment effects and risk in long-term clinical trials. Stat Med 2002;21:2899-2908.
10. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. New Engl J Med 2011; 364:11-21.
11. Leon MB, Smith CR, Mack M, Miller DC, Mosses JW, Svensson LG, Tuzcu M, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock SJ for the PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597-1607.
12. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Ostergren J, Yusuf S for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362: 759-66. (Pubitemid 37093915)